跳转至内容
Merck
CN

C2510000

Codergocrine mesilate

European Pharmacopoeia (EP) Reference Standard

别名:

Ergoloid mesylate salt, Dihydroergotoxin mesylate salt

登录查看公司和协议定价

关于此项目

CAS Number:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

codergocrine

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

CS(O)(=O)=O.CC(CO)NC(=O)C1CC2C(Cc3c[nH]c4cccc2c34)N(C)C1

InChI

1S/C19H25N3O2.CH4O3S/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13;1-5(2,3)4/h3-5,8,11,13,15,17,20,23H,6-7,9-10H2,1-2H3,(H,21,24);1H3,(H,2,3,4)

InChI key

ONYMVHQTXOEAOV-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Codergocrine mesilate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

J Olin et al.
The Cochrane database of systematic reviews, (2)(2), CD000359-CD000359 (2000-05-05)
Currently hydergine is used almost exclusively for treating patients with either dementia, or 'age-related' cognitive symptoms. Since the early eighties there have been over a dozen more clinical trials, yet hydergine's efficacy remains uncertain. Although previous reviews offer generally favorable
B L Flynn et al.
The Annals of pharmacotherapy, 33(2), 188-197 (1999-03-20)
To provide information about research evaluating antioxidants in Alzheimer disease (AD) and to discuss the potential role of beta-blockers, angiotensin-converting enzyme inhibitors, clonidine, guanfacine, nimodipine, and ergoloid derivatives in AD therapy. Studies, review articles, and editorials identified from MEDLINE searches
Ursula Werneke et al.
The British journal of psychiatry : the journal of mental science, 188, 109-121 (2006-02-02)
The use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed. To review the complementary medicines routinely encountered in psychiatric practice
A G Golden et al.
Journal of the American Geriatrics Society, 47(8), 948-953 (1999-08-12)
Little is known about the prescribing of medications in the growing population of homebound older adults. We report on the prevalence and pattern of inappropriate medications in a nursing home-eligible, homebound population. A cross-sectional design. A managed care plan for
Drugs to treat Alzheimer's disease.
Journal of psychosocial nursing and mental health services, 47(4), 13-14 (2009-05-15)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持